Articles related to MEDICAL MEETINGS AND EVENTS

Unpacking the landmark summit led by the American Pharmacists Association, it becomes clear that there is a pressing need and opportunity to expand healthcare coverage for pharmacists’ patient care services, promising substantial impacts on patient care and health systems.

Understand the profound implications of Dr. Vidal’s latest research on racial disparities in NGS testing for advanced non-small cell lung cancer, revealing a systemic issue that spans across practices and extends to the level of individual physicians.

Explore the latest findings from the VESPER trial that suggest a promising shift in bladder cancer treatment strategy, potentially setting a new standard for neoadjuvant therapy.

Age, a Critical Moderator in Anxiety/Depression and Cognitive Outcomes in MS In recent findings from the ACTRIMS Forum 2023, researchers underscored the crucial role of age in the relationship between mental health and cognitive outcomes in patients with multiple sclerosis (MS). Key Points: “Considering age is necessary when exploring the links between depression or anxiety and cognition in people with MS.” Researchers from the University of Toronto

Streamlining Oncology Communication: A New Approach to Patient-Physician Messaging A recent study presented at the 2023 ASCO Annual Meeting has shed light on the significant workload that secure patient-physician portal messages place on oncologists, prompting a call for more efficient triaging systems. Key Points: “Secure messages are now a part of healthcare delivery that directly benefits our patient access to their providers, but this comes at the expense of increased workload for oncologists.” Brandon Anderson, MD, lead author of the study and an internal medicine resident at Kaiser Permanente’s San Francisco Medical Center in California

Neoadjuvant Chemotherapy and Upfront Surgery: A Comparative Study in Resectable Pancreatic Cancer In a recent study presented at the 2023 ASCO Annual Meeting, researchers found no significant survival benefit of neoadjuvant chemotherapy over upfront surgery in patients with resectable pancreatic cancer. Key Points: “Results of this trial do not support neoadjuvant FOLFIRINOX as standard of care in resectable pancreatic cancer.” Knut Jørgen Labori, MD, PhD, Oslo University Hospital, Norway